Skip to main content
Menu
  • Meet Idylla
    • Idylla Platform
    • Oncology Tests
    • Publications
  • Oncology
    • Oncology Tests
    • Oncologist
    • Pathologist
  • Oncology Research
    • Research Assays
    • IIS Information
    • On-Demand Webinars
  • Partnering
  • Press & Events
    • Press Releases
    • Events
  • About Us
    • Team
    • Our Distributors
    • Careers
    • Download Center
    • Contact
  • IFU
  • Secure area
  • Global
  • United States
Open/Close
  • Search
  • Contact us
  • 1-844-443-9552
  • Subscribe to news
  • Global
  • United States

Unlocking Fast & Easy Molecular Classification of Endometrial Cancer Samples with the Idylla POLE-POLD1 Mutation Assay

  1. Home
  2. Publications
  3. Unlocking Fast & Easy Molecular Classification of Endometrial Cancer Samples with the Idylla POLE-POLD1 Mutation Assay
Menu
  • Meet Idylla
    • Idylla Platform
    • Oncology Tests
    • Publications
  • Oncology
    • Oncology Tests
    • Oncologist
    • Pathologist
  • Oncology Research
    • Research Assays
    • IIS Information
    • On-Demand Webinars
  • Partnering
  • Press & Events
    • Press Releases
    • Events
  • About Us
    • Team
    • Our Distributors
    • Careers
    • Download Center
    • Contact

Get access here

Please provide your email address and obtain access.

Subscribe to our latest news!

For information about the processing of your personal data please consult the Biocartis Privacy Policy.

  • Meet Idylla
  • Oncology
  • Oncology Research
  • Partnering
  • Press & Events
  • About Us

Biocartis US Inc.

2 Pierce Place, Suite 1510

Itasca, IL 60143

Phone: +1 (844) 443-9552

customerserviceUS@bio­cartis.com

 

Biocartis Global

  • Subscribe to news
  • Contact us
  • Request demo
  • Download center
  • LinkedIn
  • Facebook
  • YouTube
  • Twitter
  • Purchase conditions
  • Cookie policy
  • Privacy policy
  • Terms of use
© 2025 Biocartis Created by O2 Agency

Disclaimer

This information concerns a use that has not been approved or cleared by the Food and Drug Administration.

The opinions and conclusions expressed in the following publications are those of the individual authors and do not necessarily reflect the views and opinions of Biocartis and/or its employees.